- The FDA approves Hospira's (NYSE:HSP +1%) Dyloject (diclofenac sodium) Injection for the management of adult patients with mild-to-moderate pain and for the management of moderate-to-severe pain alone or in combination with opioid analgesics.
- Diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID). Dyloject's value proposition is the convenience of delivering a small volume IV bolus of pain medication over 15 seconds compared to other non-opioids that are formulated in large volumes or require dilution prior to administration and usually require full-dose infusion over 15 to 30 minutes.
- Hospira has had a tough time developing the product that it acquired from its takeout of Javelin Pharmaceuticals in 2010.